Life Technologies Corp (LIFE): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Life Technologies ( LIFE) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.6%. By the end of trading, Life Technologies fell 59 cents (-1.2%) to $47 on average volume. Throughout the day, 1.7 million shares of Life Technologies exchanged hands as compared to its average daily volume of 1.5 million shares. The stock ranged in price between $46.95-$47.98 after having opened the day at $47.86 as compared to the previous trading day's close of $47.59. Other companies within the Drugs industry that declined today were: Oncolytics Biotech ( ONCY), down 12.1%, Transition Therapeutics ( TTHI), down 8.8%, Lifevantage Corporation ( LFVN), down 6.7%, and Amyris ( AMRS), down 6.4%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Life Technologies Corporation operates as a global life sciences company. Life Technologies has a market cap of $8.4 billion and is part of the health care sector. The company has a P/E ratio of 19.7, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 23.2% year to date as of the close of trading on Tuesday. Currently there are nine analysts that rate Life Technologies a buy, no analysts rate it a sell, and seven rate it a hold.

TheStreet Ratings rates Life Technologies as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth, compelling growth in net income, revenue growth and attractive valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Neuralstem ( CUR), up 26.6%, GTx ( GTXI), up 19.3%, 3SBio ( SSRX), up 15.8%, and Horizon Pharma ( HZNP), up 15.2%, were all gainers within the drugs industry with Arena Pharmaceuticals ( ARNA) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.